Vivos Therapeutics, Inc.
VVOS
$2.63
-$0.08-2.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.70M | 3.86M | 4.05M | 3.42M | 3.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.70M | 3.86M | 4.05M | 3.42M | 3.25M |
| Cost of Revenue | 1.60M | 1.53M | 1.40M | 1.48M | 1.16M |
| Gross Profit | 2.10M | 2.33M | 2.65M | 1.94M | 2.09M |
| SG&A Expenses | 4.76M | 4.83M | 4.44M | 5.58M | 6.07M |
| Depreciation & Amortization | 144.00K | 146.00K | 145.00K | 146.00K | 149.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.50M | 6.51M | 5.99M | 7.20M | 7.38M |
| Operating Income | -2.81M | -2.65M | -1.94M | -3.79M | -4.13M |
| Income Before Tax | -2.83M | -2.62M | -1.93M | -3.76M | -4.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.83M | -2.62M | -1.93M | -3.76M | -4.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.83M | -2.62M | -1.93M | -3.76M | -4.26M |
| EBIT | -2.81M | -2.65M | -1.94M | -3.79M | -4.13M |
| EBITDA | -2.66M | -2.50M | -1.79M | -3.64M | -3.98M |
| EPS Basic | -0.39 | -0.61 | -0.60 | -1.63 | -3.00 |
| Normalized Basic EPS | -0.24 | -0.38 | -0.37 | -1.02 | -1.88 |
| EPS Diluted | -0.39 | -0.61 | -0.60 | -1.63 | -3.00 |
| Normalized Diluted EPS | -0.24 | -0.38 | -0.37 | -1.02 | -1.88 |
| Average Basic Shares Outstanding | 7.23M | 4.28M | 3.23M | 2.31M | 1.42M |
| Average Diluted Shares Outstanding | 7.23M | 4.28M | 3.23M | 2.31M | 1.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |